Kairasec (Candesartan Cilexetil)

Candesartan cilexetil is converted in the body to candesartan, which blocks angiotensin II type 1 receptors. This prevents angiotensin‑II‑induced vasoconstriction and aldosterone secretion, resulting in vasodilation, reduced sodium retention, and lower blood pressure.

The appropriate dose of Kairasec is determined by the prescribing clinician based on the patient’s condition, response, and renal function. Dosage adjustments are made individually; no standard regimen is provided here.

Safety of candesartan cilexetil during pregnancy has not been established and it is generally avoided because of potential fetal harm. Limited data exist for breastfeeding; clinicians usually consider alternative therapies.

To order Kairasec, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Kairasec belongs to the ARB class, offering similar blood‑pressure‑lowering efficacy to other ARBs such as losartan but with a longer half‑life and once‑daily dosing. Compared with ACE inhibitors, ARBs have a lower incidence of cough and angio‑edema.

Kairasec tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not use after the expiry date.

Kairasec is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the prescribing clinician’s instructions regarding timing and any dose adjustments.

Serious adverse events include severe hypotension, hyperkalaemia, acute kidney injury, and angio‑edema. Patients should be monitored for sudden drops in blood pressure, electrolyte disturbances, and signs of renal dysfunction, especially when initiating therapy.

Kairasec is contraindicated in patients with known hypersensitivity to candesartan or other ARBs, severe hepatic impairment, and in pregnancy. Caution is also advised for individuals with severe renal impairment or uncontrolled hyperkalaemia.